Can PTLA get new patents from new indications from future FDA approvals, like atrial fibrillation and hip or knee replacement surgery?
If PTLA doesn't already have such method-of-use patents, they won't be able to get them now. The efficacy of FXa inhibitors in these indications is already well known, and hence a new patent application would fail due to obviousness.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”